Physician profile
Narendra Siddaiah
NPI 1942225453
$2,765.58
in general payments reported to CMS, 2019-2025
27 companies · $702 in 2025
The $702 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $41.12 · 2022: $136 · 2023: $223 · 2024: $1,151 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.31 | 2019-2025 | |
| Boston Scientific Corporation | $446.03 | 2019-2025 | Watchman Access System, Resolution 360 Clip, Apollo Esg Nxt System |
| Takeda Pharmaceuticals U.S.A., INC. | $331.50 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $256.33 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.85 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $181.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $128.99 | 2024-2025 | Omvoh, Zepbound |
| Ferring Pharmaceuticals INC. | $111.19 | 2019-2023 | Rebyota |
| Pfizer INC. | $110.59 | 2019-2023 | |
| Janssen Biotech, INC. | $47.10 | 2024-2025 | Tremfya, Stelara |
| Olympus America INC. | $44.25 | 2023-2024 | Disposable Biopsy Forceps, Endoclot Phs |
| Allergan, INC. | $40.66 | 2019 | |
| Celgene Corporation | $39.47 | 2024 | Zeposia |
| Endogastric Solutions, INC | $32.10 | 2022-2023 | Esophyx |
| Medtronic, INC. | $30.91 | 2025 | Gi Genius |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $30.11 | 2025 | Esophyx |
| Aimmune Therapeutics, INC. | $30.00 | 2025 | Zenpep |
| Qol Medical, LLC | $24.15 | 2025 | Sucraid |
| Ucb, INC. | $23.01 | 2019 | |
| Gilead Sciences, INC. | $22.34 | 2022 | |
| Medtronic USA, INC. | $21.02 | 2019 | |
| Braintree Laboratories, INC. | $20.60 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.34 | 2024 | Voquezna |
| Ardelyx, INC. | $16.85 | 2025 | Ibsrela |
| Erbe USA INC | $15.89 | 2024 | |
| Merck Sharp & Dohme LLC | $12.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$49,285.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narendra Siddaiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.